Treatments in Endocrinology

, Volume 4, Issue 2, pp 127–129 | Cite as

Spotlight on Orlistat in the Management of Patients with Obesity

  • Monique P. CurranEmail author
  • Lesley J. Scott
Adis Spotlight


Orlistat is an inhibitor of gastrointestinal lipases and, therefore, prevents the absorption of dietary fat. This agent reduced weight in obese adults and adolescents with or without co-morbidities (including type 2 diabetes mellitus, hypercholesterolemia, hypertension, metabolic syndrome) who received up to 4 years of therapy in conjunction with a hypocaloric diet. In obese patients, orlistat in combination with a hypocaloric diet improved metabolic risk factors and reduced the risk of developing type 2 diabetes. Furthermore, this agent was cost effective in patients with obesity, particularly those with type 2 diabetes. Orlistat is generally well tolerated, with gastrointestinal adverse events being most commonly reported. Orlistat, in addition to lifestyle and dietary intervention, is thus an attractive option for the treatment of patients with obesity, especially those with associated co-morbidities or at risk of developing type 2 diabetes.


Obese Patient Orlistat Metabolic Risk Factor Gastrointestinal Adverse Event Hypocaloric Diet 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Hvizdos KM, Markham A. Orlistat: a review of its use in the management of obesity. Drugs 1999 Oct; 58(4): 743–60PubMedCrossRefGoogle Scholar
  2. 2.
    Guerciolini R. Mode of action of orlistat. Int J Obes 1997; 21Suppl. 3: S12–23Google Scholar
  3. 3.
    Zhi J, Melia AT, Guerciolini R, et al. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 1994; 56(1): 82–5PubMedCrossRefGoogle Scholar
  4. 4.
    Borovicka J, Schwizer W, Guttmann G, et al. Role of lipase in the regulation of postprandial gastric acid secretion and emptying of fat in humans: a study with orlistat, a highly specific lipase inhibitor. Gut 2000 Jun; 46(6): 774–81PubMedCrossRefGoogle Scholar
  5. 5.
    Wauters M, Considine RV, Van Gaal LF. Human leptin: from an adipocyte hormone to an endocrine mediator. Eur J Endocrinol 2000; 143(3): 293–311PubMedCrossRefGoogle Scholar
  6. 6.
    Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004 Jan; 27(1): 155–61PubMedCrossRefGoogle Scholar
  7. 7.
    Lucas CP, Boldrin MN, Reaven GM. Effect of orlistat added to diet (30% of calories from fat) on plasma lipids, glucose, and insulin in obese patients with hypercholesterolemia. Am J Cardiol 2003 Apr 15; 91(8): 961–4PubMedCrossRefGoogle Scholar
  8. 8.
    Guy-Grand B, Drouin P, Eschwege E, et al. Effects of orlistat on obesity-related diseases: a six-month randomized trial. Diabetes Obes Metab 2004 Sep; 6(5): 375–83PubMedCrossRefGoogle Scholar
  9. 9.
    Erdmann J, Lippl F, Klose G, et al. Cholesterol lowering effect of dietary weight loss and orlistat treatment: efficacy and limitations. Aliment Pharmacol Ther 2004 Jun 1; 19(11): 1173–9PubMedCrossRefGoogle Scholar
  10. 10.
    Muls E, Kolanowski J, Scheen A, et al. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int J Obes Relat Metab Disord 2001 Nov; 25(11): 1713–21PubMedCrossRefGoogle Scholar
  11. 11.
    Broom I, Hughes E, Dodson P, et al. The role of orlistat in the treatment of obese patients with mild to moderate hypercholesterolaemia: consequences for coronary risk. Br J Cardiol 2002; 9(8): 460–8Google Scholar
  12. 12.
    Hanefeld M, Sachse G. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebocontrolled trial. Diabetes Obes Metab 2002 Nov; 4(6): 415–23PubMedCrossRefGoogle Scholar
  13. 13.
    Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes: a 1-year randomized double-blind study. Diabetes Care 1998 Aug; 21(8): 1288–94PubMedCrossRefGoogle Scholar
  14. 14.
    Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002 Jul; 25(7): 1123–8PubMedCrossRefGoogle Scholar
  15. 15.
    Shi Y-F, Pan C-Y, Gao Y. Orlistat improves glycaemic control and weight loss in overweight and obese Chinese patients with newly diagnosed and previously untreated type 2 diabetes [abstract no. 691]. Diabetologia 2004; 47Suppl. 1: A250Google Scholar
  16. 16.
    Kelley DE, Bray GA, Pi-Sunyer FX, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2002 Jun; 25(6): 1033–41PubMedCrossRefGoogle Scholar
  17. 17.
    Halpern A, Mancini MC, Suplicy H, et al. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients. Diabetes Obes Metab 2003 May; 5(3): 180–8PubMedCrossRefGoogle Scholar
  18. 18.
    Bakris G, Calhoun D, Egan B, et al. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens 2002 Nov; 20(11): 2257–67PubMedCrossRefGoogle Scholar
  19. 19.
    Bloch KV, Salles GF, Muxfeldt ES, et al. Orlistat in hypertensive overweight/ obese patients: results of a randomized clinical trial. J Hypertens 2003 Nov; 21(11): 2159–65PubMedCrossRefGoogle Scholar
  20. 20.
    Ozcelik O, Dogan H, Kelestimur H. Effects of a weight-reduction program with orlistat on serum leptin levels in obese women: a 12-week, randomized, placebo-controlled study. Curr Ther Res Clin Exp 2004 Mar; 65(2): 127–37CrossRefGoogle Scholar
  21. 21.
    Rissanen P, Vahtera E, Krusius T, et al. Weight change and blood coagulability and fibrinolysis in healthy obese women. Int J Obes Relat Metab Disord 2001 Feb; 25: 212–8PubMedCrossRefGoogle Scholar
  22. 22.
    Karhunen L, Franssila-Kallunki A, Rissanen P, et al. Effect of orlistat treatment on body composition and resting energy expenditure during a two-year weight-reduction programme in obese Finns. Int J Obes Relat Metab Disord 2000 Dec; 24(12): 1567–72PubMedCrossRefGoogle Scholar
  23. 23.
    Chanoine J-P, Hauptman J, Boldrin M, et al. Beneficial effects on orlistat on weight and body composition in obese adolescents [abstract no. T7b:P7b-030 plus poster]. Int J Obes 2004; 28Suppl. 1: S195Google Scholar
  24. 24.
    Trouillot TE, Pace DG, McKinley C, et al. Orlistat maintains biliary lipid composition and hepatobiliary function in obese subjects undergoing moderate weight loss. Am J Gastroenterol 2001 Jun; 96(6): 1888–94PubMedCrossRefGoogle Scholar
  25. 25.
    Zhi J, Mulligan TE, Hauptman JB. Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients. J Clin Pharmacol 1999 Jan; 39(1): 41–6PubMedCrossRefGoogle Scholar
  26. 26.
    Zhi J, Melia AT, Funk C, et al. Metabolic profiles of minimally absorbed orlistat in obese/overweight volunteers. J Clin Pharmacol 1996; 36(11): 1006–11PubMedCrossRefGoogle Scholar
  27. 27.
    Zhi J, Moore R, Kanitra L, et al. Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects. J Clin Pharmacol 2002 Sep; 42(9): 1011–9PubMedGoogle Scholar
  28. 28.
    Broom I, Wilding J, Stott P, et al. Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multi-morbidity Study. Int J Clin Pract 2002 Sep; 56(7): 494–9PubMedGoogle Scholar
  29. 29.
    Krempf M, Louvet JP, Allanic H, et al. Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity. Int J Obes Relat Metab Disord 2003 May; 27(5): 591–7PubMedCrossRefGoogle Scholar
  30. 30.
    Lindgarde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J Intern Med 2000 Sep; 248(3): 245–54PubMedCrossRefGoogle Scholar
  31. 31.
    Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281(3): 235–42PubMedCrossRefGoogle Scholar
  32. 32.
    Hauptman J, Lucas C, Boldrin MN, et al. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 2000 Feb; 9(2): 160–7PubMedCrossRefGoogle Scholar
  33. 33.
    Rossner S, Sjostrom L, Noack R, et al. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity: European Orlistat Obesity Study Group. Obes Res 2000 Jan; 8(1): 49–61PubMedCrossRefGoogle Scholar
  34. 34.
    Sjostrom L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients: European Multicentre Orlistat Study Group. Lancet 1998 Jul 18; 352(9123): 167–72PubMedCrossRefGoogle Scholar
  35. 35.
    Broom I, Lindgarde F, Guy-Grand B, et al. Weight loss at lead-in is not a predictor for weight loss success with orlistat in patients with multimorbidities. Int J Obes 2004; 28Suppl. 1: S152Google Scholar
  36. 36.
    Rissanen A, Lean M, Rossner S, et al. Predictive value of early weight loss in obesity management with orlistat: an evidence-based assessment of prescribing guidelines. Int J Obes Relat Metab Disord 2003 Jan; 27(1): 103–9PubMedCrossRefGoogle Scholar
  37. 37.
    Torgerson JS, Hauptman J, Boldrin M, et al. Efficacy of orlistat plus lifestyle changes in risk reduction of type 2 diabetes in obese patients with metabolic syndrome: a comparative analysis using National Cholesterol Education Program Adult Treatment Panel III vs European group for the study of insulin resistance criteria [abstract no. 690]. Diabetologia 2004; 47Suppl. 1: A249Google Scholar
  38. 38.
    Caterson I, Guy-Grand B, Hill J. Efficacy of orlistat in overweight and obese patients with metabolic syndrome [abstract plus poster presented at the 12th European Congress on Obesity; 2003 May 29–Jun 1; Helsinki]. Int J Obes Relat Metab Disord 2003 Sep 9; 27: 1139CrossRefGoogle Scholar
  39. 39.
    Jacob S, Ziegler O, Toplak H, et al. Orlistat improves all components of the metabolic syndrome in overweight and obese patients on two diets [abstract no. T5P5b-011 plus poster presented at the 13th European Congress on Obesity; 2004 May 26–9; Prague]. Int J Obes 2004; 28Suppl. 1: S154Google Scholar
  40. 40.
    Lamotte M, Annemans L, Lefever A, et al. A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients. Diabetes Care 2002 Feb; 25(2): 303–8PubMedCrossRefGoogle Scholar
  41. 41.
    Maetzel A, Ruof J, Covington M, et al. Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus. Pharmacoeconomics 2003; 21(7): 501–12PubMedCrossRefGoogle Scholar
  42. 42.
    Finer N, James WP, Kopelman PG, et al. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord 2000 Mar; 24(3): 306–13PubMedCrossRefGoogle Scholar
  43. 43.
    Hill JO, Hauptman J, Anderson JW. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-year study. Am J Clin Nutr 1999; 69: 1108–16PubMedGoogle Scholar
  44. 44.
    McDuffie JR, Calis KA, Uwaifo GI, et al. Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions. Obes Res 2002 Jul; 10(7): 642–50PubMedCrossRefGoogle Scholar
  45. 45.
    Zhi J, Moore R, Kanitra L. The effect of short-term (21-day) orlistat treatment on the physiologic balance of six selected macrominerals and microminerals in obese adolescents. J Am Coll Nutr 2003 Oct; 22(5): 357–62PubMedGoogle Scholar
  46. 46.
    McDuffie JR, Calis KA, Booth SL, et al. Effects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy 2002 Jul; 22: 814–22PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  1. 1.Adis International LimitedYardleyUSA

Personalised recommendations